¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ½ÃÀå ±Ô¸ð, ¿¹Ãø, Á¡À¯À², µ¿Çâ, ¼ºÀå±âȸ ºÐ¼® º¸°í¼ - Á¦Ç° À¯Çüº°, °ø±Þ¿øº°, ¿ëµµº°, Ä¡·á ºÐ¾ßº°, Áö¿ªº°(2021-2031³â)
Biopharmaceutical Contract Manufacturing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Source, Application, Therapeutic Area, and Geography
»óǰÄÚµå
:
1761162
¸®¼Ä¡»ç
:
The Insight Partners
¹ßÇàÀÏ
:
2025³â 06¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 243 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2024³â 409¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 1,010¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2031³â CAGR 13.8%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ´ë, ºñ¿ëÈ¿À² ¹× À¯¿¬¼º¿¡ ´ëÇÑ ¼ö¿ä Áõ´ë´Â ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ðÀÇ È®´ë¿¡ ±â¿©ÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ¿¹»êÀÇ Ç̹ڰú °æÁ¦ÀÇ ºÒÈ®½Ç¼ºÀÌ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù.
´ÜÀÏŬ·ÐÇ×ü, À¯ÀüÀÚ Ä¡·á, ¼¼Æ÷ ±â¹Ý Ä¡·á´Â º¸´Ù Çõ½ÅÀûÀ̰í ÇÕ¸®ÀûÀÎ Á¦Á¶ °øÁ¤ÀÇ Çʿ伺À» âÃâÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Á¶ ¼öŹ ±â°ü(CMO)Àº ¿¬¼Ó Á¦Á¶, ÀÚµ¿È, ÀΰøÁö´É(AI), ÇÁ·Î¼¼½º ºÐ¼®±â¼ú(PAT) µî ¼±Áø ±â¼úÀ» äÅÃÇØ »ý»ê´É·ÂÀ» °ÈÇÏ°í ¹ÙÀÌ¿ÀÀǾàǰ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ´Â ¿òÁ÷ÀÓÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ¿¬¼Ó Á¦Á¶´Â, »ý¹° Á¦Á¦ÀÇ ¿¬¼Ó »ý»êÀ» °¡´ÉÇÏ°Ô ÇØ, Àϰü¼º, ½ºÇǵå, È¿À²À» ³ôÀÌ´Â °ÍÀ¸·ÎºÎÅÍ, ¹ÙÀÌ¿À ÀǾàǰ ¾÷°è¿¡¼ ±Þ¼ÓÈ÷ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î¼¼½º¸¦ ÅëÇØ Á¦Á¶ °øÁ¤ °£ÀÇ ´Ù¿îŸÀÓÀÌ ´ÜÃàµÇ°í Áß°£ ÀúÀåÀÇ Çʿ伺ÀÌ ÃÖ¼ÒȵǹǷΠÁ¦Á¶ ºñ¿ëÀÌ ´ëÆø Àý°¨µË´Ï´Ù. º£ÀÌÄ¿ ¸ÅÄËÁöÀÇ º¸°í¼¿¡ µû¸£¸é, ¿¬¼Ó Á¦Á¶´Â »ý¹° Á¦Á¦ÀÇ Á¦Á¶ ºñ¿ëÀ» 30% Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ë¹ÙƼ½º¿Í ÈÀÌÀÚ´Â ´ë±Ô¸ð »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶¿¡ ¿¬¼Ó Á¦Á¶¸¦ µµÀÔÇϰí ÀÖ´Â ´ë±â¾÷ Áß Çϳª·Î, ¾÷¹« È¿À² °³¼±°ú ºñ¿ë Àý°¨¿¡ È¿°úÀûÀÓÀ» º¸¿©ÁÝ´Ï´Ù.
ÀΰøÁö´É(AI)Àº °øÁ¤ ÃÖÀûÈ, ¿¹Áöº¸Àü, ǰÁú°ü¸®¿¡µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. AI ±â¹Ý µµ±¸´Â ¹æ´ëÇÑ ¾çÀÇ »ý»ê µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ºÐ¼®ÇØ ÀáÀçÀûÀÎ ¹®Á¦°¡ ¹ß»ýÇϱâ Àü¿¡ ÆÄ¾ÇÇÏ°í »ý»ê ÇÁ·Î¼¼½º Àüü¸¦ ÅëÇØ ÃÖÀûÀÇ »óŸ¦ È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº CMO°¡ ´Ù¿îŸÀÓÀ» ÃÖ¼ÒÈÇÏ°í ¼öÀ²À» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÄÚ±×´ÏÀÜÆ®¿Í °°Àº ±â¾÷Àº ÀÌ¹Ì AI¸¦ »ç¿ëÇÏ¿© Á¦Á¶ ÇÁ·Î¼¼½ºÀÇ ÀáÀçÀûÀÎ ¿À·ù¸¦ ¿¹ÃøÇϰí ÀÇ»ç°áÁ¤À» °³¼±Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÇÁ·Î¼¼½º ºÐ¼® ±â¼ú(PAT)Àº, Áß¿äÇÑ ÇÁ·Î¼¼½º ÆÄ¶ó¹ÌÅÍÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú Á¦¾î¸¦ °¡´ÉÇÏ°Ô ÇØ, »ý¹° Á¦Á¦ÀÇ ´ë±Ô¸ð ¹èÄ¡ Àüü¿¡¼ ÀϰüµÈ ǰÁúÀ» º¸ÁõÇÕ´Ï´Ù. PAT¸¦ ÅëÇÕÇÔÀ¸·Î½á Á¦Á¶¾÷ü´Â Á¦Á¶ °øÁ¤ÀÇ ºü¸¥ ´Ü°è¿¡¼ ÆíÂ÷¸¦ °ËÃâÇÏ°í °áÇÔÀ̳ª ºÎÁ¤ÇÕÀ» ¹æÁöÇϱâ À§ÇØ ½Ç½Ã°£À¸·Î Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Ç°ÀÇ Ç°ÁúÀÌ Çâ»óµÇ°í ¸®¼Ò½º¸¦ º¸´Ù È¿À²ÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ½Ã°£°ú ºñ¿ë ¸ðµÎ Àý°¨µË´Ï´Ù. µû¶ó¼ ¿¬¼Ó Á¦Á¶, ÀÚµ¿È, AI, PAT µî °íµµÀÇ Á¦Á¶±â¼ú äÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ÇâÈÄ ¼ö³â°£ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Ä¡·á ¿µ¿ª ±â¹Ý ÀλçÀÌÆ®
Ä¡·á ºÐ¾ß¿¡ µû¶ó ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀº Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ, È£Èí±âÁúȯ, ´ë»çÁúȯ, ½Å°æÇÐ, °¨¿°Áõ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå Á¡À¯À²Àº ¾Ï ºÐ¾ß°¡ ÃÖ´ë¿´½À´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ ¼¼°è »çÀÎÀÇ 1À§À̱⠶§¹®¿¡ ¼±ÁøÀûÀÎ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î 2,000¸¸ ¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ¿Í 970¸¸ ¸íÀÇ ¾Ï °ü·Ã »ç¸ÁÀÌ º¸°íµÇ¾ú½À´Ï´Ù. ÀÌ ¼ö¿ä´Â ÁÖ·Î »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß¿¡ ÀÇÇØ ÃÊ·¡µÇ°í ÀÖÀ¸¸ç, »ý¹°ÇÐÀû Á¦Á¦ÀÇ Á¦Á¶¿¡´Â º¹ÀâÇÑ ¼¼Æ÷¹è¾ç ½Ã½ºÅÛ°ú ¾ö°ÝÇÑ Ç°Áú°ü¸® Á¶Ä¡°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ¸¹Àº Á¦¾à±â¾÷¿¡¼ Á¦Á¶À§Å¹Ã³·ÎÀÇ ¾Æ¿ô¼Ò½ÌÀº ½ÇÇà °¡´ÉÇÑ ¼Ö·ç¼ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù. ŰƮ·ç´Ù´Â 2024³â 294¾ï 8,000¸¸ ´Þ·¯ÀÇ ¸ÅÃâ¾×À» ±â·ÏÇßÀ¸¸ç, ¾Ï »ý¹°ÇÐÀû Á¦Á¦ÀÇ °Å´ëÇÑ ½ÃÀå ÀáÀç·ÂÀ» ºÎ°¢½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ Æ¯È÷ Kymriah(tisagen lecleucel)³ª Yescarta(axicabtagene ciloleucel) µîÀÇ CAR-T ¿ä¹ýÀ» Áß½ÉÀ¸·Î ÇÑ °³º°ÈÁ¾¾ç Ä¡·á¿¡ ´ëÇÑ °æÇâÀÇ °íÁ¶µµ °íµµ·Î Àü¹®ÈµÈ ¼öŹÁ¦Á¶ÀÇ Çʿ伺¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¿¡´Â À¯ÀüÀÚ Á¶ÀÛ ¸é¿ª¼¼Æ÷ÀÇ »ý»êÀÌ ÇÊ¿äÇϰí, ¼¼Æ÷ Ä¡·á³ª À¯ÀüÀÚ Ä¡·á¿¡ Á¤ÅëÇÑ CMO¿¡ ´ëÇÑ ¼ö¿ä°¡ »ý°Ü, ¹ÙÀÌ¿À ÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO), ¼¼°èÀÚ°¡¸é¿ª¿¬±¸¼Ò(Global Autoimmune Institute 2022) º¸°í¼, ±¹Á¦´ç´¢º´¿¬ÇÕ(International Diabetes Federation) µîÀº ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå º¸°í ÀÛ¼º ½Ã ÂüÁ¶ÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
2Â÷ Á¶»ç
1Â÷ Á¶»ç
°¡¼³ÀÇ Ã¥Á¤
°Å½Ã°æÁ¦ ¿äÀκм®
ÆÄ¿îµ¥ÀÌ¼Ç ¼öÄ¡ÀÇ °³¹ß
µ¥ÀÌÅÍÀÇ »ï°¢Ãø·®
±¹°¡ ·¹º§ µ¥ÀÌÅÍ
°¡Á¤°ú ÇѰè
Á¦4Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ Á¤¼¼
Á¦5Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
»ý¹° Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
ºñ¿ë È¿À²¼º ¹× À¯¿¬¼º¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
¿¹»êÀÇ ºÎÁ· ¹× °æÁ¦ÀÇ ºÒÈ®½Ç¼º
½ÃÀå ±âȸ
¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
ÇâÈÄ µ¿Çâ
¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ
Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ½ÃÀå ºÐ¼®
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼öÀÍ(2021-2031³â)
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¿¹Ãø ºÐ¼®
Á¦7Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°
Á¦8Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : °ø±Þ¿øº°
Á¦9Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : ¿ëµµº°
Á¦10Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : Ä¡·á ºÐ¾ßº°
¾Ï ¿µ¿ª
ÀÚ°¡¸é¿ªÁúȯ
È£Èí±â Áúȯ
´ë»çÁúȯ
½Å°æÇÐ
°¨¿°Áõ
±âŸ
Á¦11Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : Áö¿ªº° ºÐ¼®
ºÏ¹Ì
À¯·´
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áß±¹
ÀϺ»
Àεµ
È£ÁÖ
Çѱ¹
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
»ç¿ìµð¾Æ¶óºñ¾Æ
³²¾ÆÇÁ¸®Ä«
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áß³²¹Ì
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
±âŸ Áß³²¹Ì
Á¦12Àå °æÀï ±¸µµ
ÁÖ¿ä ±â¾÷ÀÇ È÷Æ®¸Ê ºÐ¼®
±â¾÷ÀÇ Æ÷Áö¼Å´× ¹× ÁýÁßµµ
Á¦13Àå ¾÷°è Á¤¼¼
»ç¾÷ È®´ë
½ÅÁ¦Ç° °³¹ß
ÇÕº´ ¹× Àμö
ÆÄÆ®³Ê½Ê
±âŸ »ç¾÷ Àü·«
Á¦14Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
Boehringer Ingelheim International GmbH
Lonza Group AG
Samsung Biologics Co Ltd
Merck KGaA
AbbVie Inc
WuXi Biologics Inc
Ajinomoto Co Inc
Cytiva
AGC Biologics AS
Á¦15Àå ºÎ·Ï
AJY
¿µ¹® ¸ñÂ÷
The biopharmaceutical contract manufacturing market size is expected to grow from US$ 40.99 billion in 2024 to US$ 101.05 billion by 2031; it is projected to register a CAGR of 13.8% during 2025-2031. Rising demand for biologics and increasing demand for cost efficiency and flexibility are noteworthy factors contributing to the expansion of the biopharmaceutical contract manufacturing market size. However, the tightened budget and economic uncertainty hinder the biopharmaceutical contract manufacturing market growth.
Monoclonal antibodies, gene therapies, and cell-based treatments have created the need for more innovative, streamlined manufacturing processes. As a result, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies such as continuous manufacturing, automation, artificial intelligence (AI), and process analytical technologies (PAT) to enhance production capabilities and meet the growing demand for biopharmaceuticals. Continuous manufacturing is rapidly gaining traction in the biopharmaceutical industry as it allows the uninterrupted production of biologics, providing greater consistency, speed, and efficiency. This process reduces downtime between production runs and minimizes the need for intermediate storage, significantly reducing production costs. According to a Baker McKenzie report, continuous manufacturing can reduce the cost of biologic production by 30%. Novartis and Pfizer are among the major companies implementing continuous manufacturing for large-scale biologic production, demonstrating its effectiveness in improving operational efficiency and reducing costs.
Artificial intelligence (AI) can also be used for process optimization, predictive maintenance, and quality control. AI-based tools can analyze vast amounts of production data in real-time, identifying potential issues before they arise and ensuring optimal conditions throughout the production process. This technology helps CMOs minimize downtime and improve yield rates. Companies such as Cognizant are already using AI to predict potential failures in manufacturing processes and improve decision-making. Furthermore, process analytical technologies (PAT) enable real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By integrating PAT, manufacturers can detect variations early in the production process and adjust in real-time to prevent defects or inconsistencies. This results in higher-quality products and more efficient use of resources, reducing both time and cost. Therefore, the increasing adoption of advanced manufacturing technologies such as continuous manufacturing, automation, AI, and PAT is expected to contribute to the growth of the biopharmaceutical contract manufacturing market in the coming years.
Therapeutic Area-Based Insights
Based on the therapeutic area, the biopharmaceutical contract manufacturing market is segmented into oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. The oncology segment held the largest biopharmaceutical contract manufacturing market share in 2024. As cancer remains a leading cause of death globally, it drives the need for advanced cancer treatments. According to the World Health Organization (WHO), 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. This demand is primarily driven by the development of biologics and the production of biologics involves complex cell culture systems and stringent quality control measures, making outsourcing to contract manufacturers a viable solution for many pharmaceutical companies. Keytruda generated US$ 29.48 billion in sales in 2024, highlighting the immense market potential of oncology biologics. Additionally, the increasing trend toward personalized oncology treatments, particularly with CAR-T therapies such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), has also fueled the need for highly specialized contract manufacturing. These treatments require the production of genetically modified immune cells, which creates the demand for CMOs with expertise in cell and gene therapies, thereby fueling the biopharmaceutical contract manufacturing market growth.
World Health Organization (WHO), Global Autoimmune Institute 2022 report, and International Diabetes Federation are among the primary and secondary sources referred to while preparing the biopharmaceutical contract manufacturing market report.
Table Of Contents
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
3.3 Assumptions and Limitations
4. Biopharmaceutical Contract Manufacturing Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
5.1 Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
5.2 Market Drivers:
5.2.1 Rising Demand for Biologics
5.2.2 Increasing Demand for Cost Efficiency and Flexibility
5.3 Market Restraints
5.3.1 Tightened Budget and Economic Uncertainty
5.4 Market Opportunities
5.4.1 Increasing Demand for Personalized Medicine
5.5 Future Trends
5.5.1 Advanced Manufacturing Technologies
5.6 Impact of Drivers and Restraints:
6. Biopharmaceutical Contract Manufacturing Market - Global Market Analysis
6.1 Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2021-2031
6.2 Biopharmaceutical Contract Manufacturing Market Forecast Analysis
7. Biopharmaceutical Contract Manufacturing Market Analysis - by Product Type
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8. Biopharmaceutical Contract Manufacturing Market Analysis - by Source
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9. Biopharmaceutical Contract Manufacturing Market Analysis - by Application
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10. Biopharmaceutical Contract Manufacturing Market Analysis - by Therapeutic Area
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
11. Biopharmaceutical Contract Manufacturing Market - Geographical Analysis
11.1 North America
11.1.1 North America Biopharmaceutical Contract Manufacturing Market Overview
11.1.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
11.1.2.1 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
11.1.2.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
11.1.2.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
11.1.2.4 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
11.1.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
11.1.3.1 United States: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.1.3.1.1 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.1.3.1.2 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.1.3.1.3 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.1.3.1.4 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.1.3.2 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.1.3.2.1 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.1.3.2.2 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.1.3.2.3 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.1.3.2.4 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.1.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.1.3.3.1 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.1.3.3.2 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.1.3.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.1.3.3.4 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2 Europe
11.2.1 Europe Biopharmaceutical Contract Manufacturing Market Overview
11.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
11.2.2.1 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
11.2.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
11.2.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
11.2.2.4 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
11.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
11.2.3.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.1.1 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.1.2 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.1.3 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.1.4 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2.3.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.2.1 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.2.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.2.3 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.2.4 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2.3.3 France: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.3.1 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.3.2 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.3.3 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.3.4 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2.3.4 Italy: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.4.1 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.4.2 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.4.3 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.4.4 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2.3.5 Spain: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.5.1 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.5.2 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.5.3 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.5.4 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.2.3.6 Rest of Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.2.3.6.1 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.2.3.6.2 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.2.3.6.3 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.2.3.6.4 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3 Asia Pacific
11.3.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Overview
11.3.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
11.3.2.1 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
11.3.2.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
11.3.2.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
11.3.2.4 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
11.3.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
11.3.3.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.1.1 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.1.2 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.1.3 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.1.4 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3.3.2 Japan: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.2.1 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.2.2 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.2.3 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.2.4 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3.3.3 India: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.3.1 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.3.2 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.3.3 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.3.4 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3.3.4 Australia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.4.1 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.4.2 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.4.3 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.4.4 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3.3.5 South Korea: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.5.1 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.5.2 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.5.3 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.5.4 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.3.3.6 Rest of APAC: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.3.3.6.1 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.3.3.6.2 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.3.3.6.3 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.3.3.6.4 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.4 Middle East & Africa
11.4.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Overview
11.4.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
11.4.2.1 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
11.4.2.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
11.4.2.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
11.4.2.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
11.4.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
11.4.3.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.4.3.1.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.4.3.1.2 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.4.3.1.3 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.4.3.1.4 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.4.3.2 South Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.4.3.2.1 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.4.3.2.2 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.4.3.2.3 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.4.3.2.4 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.4.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.4.3.3.1 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.4.3.3.2 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.4.3.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.4.3.3.4 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.4.3.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.4.3.4.1 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.4.3.4.2 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.4.3.4.3 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.4.3.4.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.5 South & Central America
11.5.1 South & Central America Biopharmaceutical Contract Manufacturing Market Overview
11.5.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
11.5.2.1 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
11.5.2.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
11.5.2.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
11.5.2.4 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
11.5.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
11.5.3.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.5.3.1.1 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.5.3.1.2 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.5.3.1.3 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.5.3.1.4 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.5.3.2 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.5.3.2.1 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.5.3.2.2 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.5.3.2.3 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.5.3.2.4 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
11.5.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
11.5.3.3.1 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
11.5.3.3.2 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
11.5.3.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
11.5.3.3.4 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
12. Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13. Industry Landscape
13.1 Overview
13.2 Expansion
13.3 New Product Development
13.4 Merger and Acquisition
13.5 Partnerships
13.6 Other Business Strategies
14. Company Profiles
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Samsung Biologics Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Merck KGaA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 AbbVie Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 WuXi Biologics Inc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
°ü·ÃÀÚ·á